The Asia-Pacific epigenetics diagnostic market is projected to register a CAGR of 18.3% in the forecast period of 2021 to 2028. The new market report contains data for the historic year 2019, the base year of calculation is 2020, and the forecast period is 2021 to 2028
Market Segmentation:
Asia-Pacific Epigenetics Diagnostic Market, By Product (Reagents, Kits, Instruments & Consumables, Bioinformatics Tools & Enzymes), Technology (DNA Methylation, Histone Methylation, Chromatin Structures, Histone Acetylation, Large Non-Coding RNA & MicroRNA Modification), Type of Therapy (Histone Deacetylase (HDAC) Inhibitors, DNA Methyltransferase (DNMT) Inhibitors & Others), Application (Oncology, Cardiovascular Diseases, Metabolic Diseases, Immunology, Inflammatory Diseases, Infectious Diseases & Others), End User (Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, Contract Research Organizations (CROs) & Others), Distribution Channel (Direct Tender & Retail Sales), Country (Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific) Industry Trends and Forecast to 2028
Some of the major factors contributing to the growth of the Asia-Pacific epigenetics diagnostic market are:
High prevalence of chronic diseases such as cancer
Increasing R&D activities associated with epigenetics
Market Players:
The major companies which are dealing in the Asia-Pacific epigenetics diagnostic market are listed below:
PerkinElmer Inc.
Diagenode
F. Hoffman-La Roche Ltd
EPICYPHER
Promega Corporation
QIAGEN
Pacific Biosciences of California, Inc.
Epigenomics AG
Reaction Biology
Bio-Rad Laboratories, Inc.
Agilent Technologies, Inc.
Merck KGaA
Illumina, Inc.
ACTIVEMOTIF
Thermo Fisher Scientific, Inc.
EpiGentek Group Inc.
Enzo Life Sciences, Inc.
GlaxoSmithKline plc.
MDxHealth
Abcam plc
Salarius Pharmaceuticals, Inc.
TABLE OF CONTENT
Segmentation
Short Description
Asia-Pacific Epigenetics Diagnostic Market, By Product (Reagents, Kits, Instruments & Consumables, Bioinformatics Tools & Enzymes), Technology (DNA Methylation, Histone Methylation, Chromatin Structures, Histone Acetylation, Large Non-Coding RNA & MicroRNA Modification), Type of Therapy (Histone Deacetylase (HDAC) Inhibitors, DNA Methyltransferase (DNMT) Inhibitors & Others), Application (Oncology, Cardiovascular Diseases, Metabolic Diseases, Immunology, Inflammatory Diseases, Infectious Diseases & Others), End User (Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, Contract Research Organizations (CROs) & Others), Distribution Channel (Direct Tender & Retail Sales), Country (Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific) Industry Trends and Forecast to 2028
Market Definition:
The epigenetics diagnostic is the study of genetics, cellular and physical trait variations and developmental biology which is caused by the external environmental. This in turn affects genes and cellular ability to read genes without being affected by changes in genotype. The epigenetics changes result into changes in phenotype of organism rather than genotype, the underlying DNA and RNA sequence remains unchanged. The epigenetic changes are essential for development as they are dynamic and change with respect to environment.
The genetic expressions of organism are effected by epigenetics, which is making it the most crucial field of molecular biology and developmental genetics. Organizations, such as the National Center Institute, the National Institute of Health, and the International Human Epigenome Consortium, are funding and supporting research and development activities pertaining to the field of epigenetics. Epigenetics is also used to treat a variety of chronic diseases such as cancer, metabolic diseases, and others.
Market Segmentation:
Asia-Pacific epigenetics diagnostic market is categorized into six notable segments, which are based on product, technology, type of therapy, application, end user, and distribution channel.
On the basis of product, the epigenetics diagnostic market is segmented into reagents, kits, instruments & consumables, bioinformatics tools, and enzymes
On the basis of technology, the epigenetics diagnostic market is segmented into DNA methylation, histone methylation, chromatin structures, histone acetylation, large non-coding RNA, and microRNA modification
On the basis of type of therapy, the epigenetics diagnostic market is segmented into histone deacetylase (HDAC) inhibitors, DNA methyltransferase (DNMT) inhibitors, and others
On the basis of application, the epigenetics diagnostic market is segmented into oncology, cardiovascular diseases, metabolic diseases, immunology, inflammatory diseases, and others
On the basis of end user, the epigenetics diagnostic market is segmented into academic and research institutes, pharmaceutical and biotechnology companies, contract research organizations (CROs), and others
On the basis of distribution channel, the epigenetics diagnostic market is segmented into direct tender and retail sales
Market Players
The major companies which are dealing in the Asia-Pacific epigenetics diagnostic market are listed below:
PerkinElmer Inc.
Diagenode
F. Hoffman-La Roche Ltd
EPICYPHER
Promega Corporation
QIAGEN
Pacific Biosciences of California, Inc.
Epigenomics AG
Reaction Biology
Bio-Rad Laboratories, Inc.
Agilent Technologies, Inc.
Merck KGaA
Illumina, Inc.
ACTIVEMOTIF
Thermo Fisher Scientific, Inc.
EpiGentek Group Inc.
Enzo Life Sciences, Inc.
GlaxoSmithKline plc.
MDxHealth
Abcam plc
Salarius Pharmaceuticals, Inc.
Methodology
Why Choose Us
24 * 7 Access to Analyst :
Get your pre and post sales queries resolved by our Subject matter experts.
Customization :
We will assist you to customize the report to fit your research needs.
Assured Quality :
Our prime focus is to provide qualitative and accurate data.
Free sample report :
Feel free to order a sample report before purchase.
Security :
Your personal and confidential information is safe and secured.
